Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

NCT04853927 is registered in ClinicalTrials.gov with Applied Biology, Inc. as lead sponsor.

NCT NCT04853927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
Lead sponsor
Applied Biology, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
February 8, 2021
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars (severe acute respiratory syndrome)